<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - FINGOLIMOD</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>FINGOLIMOD</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of highly active relapsing-remitting multiple sclerosis in patients who have high disease activity despite treatment with at least one disease modifying therapy or in those with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms once daily.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Fingolimod is an immunomodulating drug.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid (toxicity in <i>animal</i> studies).</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution in mild to moderate impairment.</p><p>Avoid in severe impairment.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active infection</li>
            <li>active malignancies (except cutaneous basal cell carcinoma)</li>
            <li>immunosuppression</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Alopecia, AV block, back pain, blurred vision, bradycardia, bronchitis, cough, depression, diarrhoea, dizziness, dyspnoea, eczema, eye pain, gastroenteritis, headache, herpes, hypertension, influenza, leucopenia, lymphopenia, malaise, migraine, paraesthesia, pruritus, sinusitis, tinea, weight loss,
              </p>
              <p>
                <strong>uncommon:</strong> Macular oedema, neutropenia, pneumonia,
              </p>
              <p>
                <strong>notKnown:</strong> Haemophagocytic syndrome, lymphoma,
              </p>
        
        
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA254</h3>
              <p outputclass="title">Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (April 2012)</p> <p>Fingolimod is recommended as an option for the treatment of highly active relapsing-remitting multiple sclerosis in adults, only if:</p> <ul> <li>they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta, <b>and</b> </li> <li>the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme</li> </ul> <p>Patients currently receiving fingolimod whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format="html" href="http://www.nice.org.uk/TA254">www.nice.org.uk/TA254</xref>
                <a href="http://www.nice.org.uk/TA254" target="_blank">www.nice.org.uk/TA254</a>
            </section>
      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>MHRA/CHM advice: Fingolimod&amp;#8212;not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose and following treatment interruption (January 2013)</h3>
              <p>Fingolimod is known to cause transient bradycardias and heart block after the first dose. Fingolimod is not recommended in the following patient groups who are at high risk of cardiovascular events unless the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought before initiation:</p><p>
            <b>Patients with the following medical conditions</b>:</p><ul>
            <li>2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block</li>
            <li>significant QT prolongation (QT-interval greater than 470&#8239;milliseconds in women, or greater than 450&#8239;milliseconds in men)</li>
            <li>history of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnoea.</li>
            </ul><p>
            <b>Patients receiving the following antiarrhythmic or heart-rate lowering drugs</b>:</p><ul>
            <li>class Ia or class III antiarrhythmics</li>
            <li>beta blockers </li>
            <li>heart rate-lowering calcium channel blockers </li>
            <li>other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic drugs or pilocarpine).</li>
            </ul><p>
            <b>All</b> patients receiving fingolimod should be monitored at treatment initiation, (first dose monitoring), and after treatment interruption (see note below); monitoring should include:</p><p>
            <b>Pre-treatment</b>
            </p><ul>
            <li>a 12-lead ECG and blood pressure measurement before starting</li>
            </ul><p>
            <b>During the first 6 hours of treatment</b>
            </p><ul>
            <li>continuous ECG monitoring for 6 hours</li>
            <li>blood pressure and heart rate measurement every hour</li>
            </ul><p>
            <b>After 6 hours of treatment</b>
            </p><ul>
            <li>a further 12-lead ECG and blood pressure measurement</li>
            </ul><p>If heart rate at the end of the 6 hour period is at its lowest since fingolimod was first administered, monitoring should be extended by at least 2 hours and until heart rate increases.</p><p>Extended monitoring, (at least overnight), should be performed in patients with evidence of clinically important cardiac effects during first dose monitoring. Monitoring in patients requiring pharmacological intervention for bradyarrhythmia-related symptoms during first dose monitoring should be extended at least overnight, and first dose monitoring should be repeated after the second dose.</p><p>
            <b>Note</b>
            </p><p>First dose monitoring as above <b>should be repeated</b> in all patients whose treatment is interrupted for:</p><ul>
            <li>1 day or more during the first 2 weeks of treatment</li>
            <li>more than 7 days during weeks 3 and 4 of treatment</li>
            <li>more than 2 weeks after one month of treatment</li>
            </ul><p>If the treatment interruption is of shorter duration than the above, repeated monitoring is not required and treatment should be continued with the next dose as planned.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Check varicella zoster virus status&#8212;consult product literature for further information
          </li>
          <li>
            chronic obstructive pulmonary disease
          </li>
          <li>
            pulmonary fibrosis
          </li>
          <li>
            risk of macular oedema
          </li>
          <li>
            severe respiratory disease
          </li>
          <li>
            susceptibility to QT-interval prolongation (including electrolyte disturbances)
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment.</p><p>Ensure effective contraception during and for at least 2 months after treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Eye examination recommended 3&#8211;4 months after initiation of treatment (and before initiation of treatment in patients with diabetes or history of uveitis).</p><p>Monitor hepatic transaminases before treatment, then every 3 months for 1 year, then periodically thereafter.</p><p>Monitor full blood count before treatment, at 3 months, then at least yearly thereafter and if signs of infection&#8212; interrupt treatment if lymphocyte count reduced&#8212;consult product literature.</p><p>Monitor for signs and symptoms of haemophagocytic syndrome (including pyrexia, asthenia, hepato-splenomegaly and adenopathy&#8212;may be associated with hepatic failure and respiratory distress; also progressive cytopenia, elevated serum-ferritin concentrations, hypertriglyceridaemia, hypofibrinogenaemia, coagulopathy, hepatic cytolysis, hyponatraemia)&#8212;initiate treatment immediately.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of FINGOLIMOD</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75194"><a href="../medicinalForm/PHP75194.html" data-target="#PHP75194" data-action="load">Capsule</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
